Zhao G, Xu X, Ochoa M, Shen W, Hintze T H
Department of Physiology, New York Medical College, Valhalla 10595, USA.
Cardiovasc Res. 1996 Nov;32(5):940-8.
Our goal was to determine the role of nitric oxide (NO) on the coronary vasodilation induced by prostacyclin (PGI2) in conscious dogs.
Dogs were chronically instrumented for the measurements of coronary blood flow (CBF), left ventricular pressure (LVP), mean arterial pressure (MAP) and heart rate (HR).
Intravenous injections of PGI2 caused dose-dependent increases in CBF, and decreases in MAP and late diastolic coronary resistance (LDCR). For instance, CBF increased by 128 +/- 19% (P < 0.05) from 30 +/- 3.5 ml/min and LDCR decreased by 73 +/- 3% (P < 0.05) from 2.57 +/- 0.20 mmHg/ml/min following injection of PGI2 (1.0 microgram/kg). After infusion of nitro-L-arginine (NLA, 35 mg/kg) intravenously, the coronary vasodilation induced by PGI2 was partially attenuated. PGI2 (1.0 microgram/kg) increased CBF by 55 +/- 15% from 33 +/- 5.3 ml/min and decreased LDCR by 42 +/- 9% (both P < 0.05, compared with before NLA) from 3.29 +/- 0.39 mmHg/ml/min. Infusion of L-arginine (100 mg/kg) reversed the action of NLA. For example, PGI2 (1.0 microgram/kg) increased CBF by 115 +/- 15% from 36 +/- 6 ml/min and decreased LDCR by 68 +/- 3% from 3.02 +/- 0.36 mmHg/ml/min (both P > 0.05, compared with before NLA). Atropine (0.1 mg/kg) partially attenuated the coronary vasodilation induced by PGI2 the magnitude of which was almost identical to that by NLA. NLA or atropine also blunted the coronary vasodilation induced by acetylcholine, while the coronary vasodilation induced by nitroglycerin was not affected by NLA.
Our results indicate that the coronary vasodilation induced by PGI2 was partially attenuated by NLA or atropine, suggesting that the coronary vasodilation induced by PGI2 is due to two components: a reflex parasympathetic cholinergic vasodilation mediated by NO and a direct action of PGI2.
我们的目标是确定一氧化氮(NO)在清醒犬体内对前列环素(PGI2)诱导的冠状动脉舒张作用中所起的作用。
对犬进行长期仪器植入,以测量冠状动脉血流量(CBF)、左心室压力(LVP)、平均动脉压(MAP)和心率(HR)。
静脉注射PGI2导致CBF呈剂量依赖性增加,MAP和舒张末期冠状动脉阻力(LDCR)降低。例如,注射PGI2(1.0微克/千克)后,CBF从30±3.5毫升/分钟增加了128±19%(P<0.05),LDCR从2.57±0.20毫米汞柱/毫升/分钟降低了73±3%(P<0.05)。静脉输注硝基-L-精氨酸(NLA,35毫克/千克)后,PGI2诱导的冠状动脉舒张作用部分减弱。PGI2(1.0微克/千克)使CBF从33±5.3毫升/分钟增加了55±15%,LDCR从3.29±0.39毫米汞柱/毫升/分钟降低了42±9%(与NLA注射前相比,两者P<0.05)。输注L-精氨酸(100毫克/千克)可逆转NLA的作用。例如,PGI2(1.0微克/千克)使CBF从36±6毫升/分钟增加了115±15%,LDCR从3.02±0.36毫米汞柱/毫升/分钟降低了68±3%(与NLA注射前相比,两者P>0.05)。阿托品(0.1毫克/千克)部分减弱了PGI2诱导的冠状动脉舒张作用,其程度与NLA几乎相同。NLA或阿托品也减弱了乙酰胆碱诱导的冠状动脉舒张作用,而硝酸甘油诱导的冠状动脉舒张作用不受NLA影响。
我们的结果表明,NLA或阿托品部分减弱了PGI2诱导的冠状动脉舒张作用,提示PGI2诱导的冠状动脉舒张作用由两个部分组成:由NO介导的反射性副交感胆碱能舒张作用和PGI2的直接作用。